Even though currently AFP may still be the main serum biomarker for HCC surveillance, A-SAA biomarkers can be used as a complementary test in combination with imaging examination, especially for the cirrhotic patients with low AFP level. This evidence concerns the gene SAA1 and hepatocellular carcinoma.